We focused on SEC23A because it was consistently reduced at the protein level, in response to stable expression of miR-1227 in RWPE-2 and PC3 prostate cancer, as well as in U87 glioma cell lines (Figure 3B). The gene discussed is SEC23A; the disease is glioma.